Hangzhou Shanze Biopharmaceutical

Hangzhou Shanze Biopharmaceutical is a clinical-stage biotechnology company based in Hangzhou, China, dedicated to the discovery and development of next-generation antibody-based therapies for cancer. The company's research and development efforts are centered on high-value oncology targets, including Claudin 18.2 and PD-L1. Its lead program, SZ-001, is a monoclonal antibody targeting Claudin 18.2 that has entered Phase 1 clinical testing for advanced solid tumors. Shanze Biopharmaceutical leverages its internal expertise in protein engineering to create a pipeline of monoclonal and bispecific antibodies designed to overcome resistance to current immunotherapies. The company aims to provide more effective treatment options for patients with gastrointestinal and other difficult-to-treat cancers. Founded in 2021, the firm is part of the growing ecosystem of innovative biopharmaceutical startups in the Zhejiang region.